eligibility_summary
Adults (≥18) with advanced/metastatic CD70+ solid tumors after standard therapy failure/intolerance, measurable (RECIST 1.1), ECOG 0–2, >12‑week survival, adequate organ function, apheresis eligible, contraception and consent required. Exclude prior anti‑CD70, active/unstable CNS mets, recent trials/therapy/high‑dose steroids/live vaccine, active infection, other active cancers, major cardiac/autoimmune disease, HBV/HCV viremia, HIV/syphilis/CMV+, VTE on anticoag, uncontrolled HTN, pregnancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I, open-label, two-arm study testing CD70-targeted CAR-T cells in CD70-positive advanced/metastatic solid tumors (e.g., RCC, ovarian, cervical). Interventions: CD70 CAR-T cells (genetically engineered autologous T-cell therapy) administered either intravenously or intraperitoneally at 1–10×10^6 cells/kg after lymphodepletion with fludarabine (purine antimetabolite) and cyclophosphamide (alkylating agent). Mechanism: The CAR enables MHC-independent recognition of CD70, triggering T-cell activation, cytokine release, and cytotoxic killing of CD70+ tumor cells, lymphodepletion reduces cytokine sink and supports CAR-T expansion. Targets: CD70 on tumor cells, impacting the CD70/CD27 pathway, and engaging T-cell activation signaling via the CAR (CD3ζ with costimulation, not specified).